Quantcast

Possible Alzheimer’s Vaccine

April 27, 2012

(Ivanhoe Newswire) — Alzheimer´s disease (AD) is the leading cause of dementia in the elderly and is an incurable disease that affects more than five million people. Now intravenous human immunoglobulin (IVIG) treatment is currently being explored for uses other than immunotherapy, including AD. Several studies are assessing the tolerability and efficacy of IVIG in Alzheimer´s patients. Recent studies by Dr. Giulio Maria Pasinetti, Saunders Family Chair and Professor in Neurology and Psychiatry at Mount Sinai School of Medicine in New York, demonstrate that the diverse outcomes in AD studies of IVIG may be due to differences in temporal administration and administered doses.

The study found that prolonged administration of human immunoglobulin in models of AD, using a dose of immunoglobulin, 5-20x less than equivalent doses used in Alzheimer’s disease patients, is effective at lessening Alzheimer’s disease-type cognitive dysfunction while promoting synaptic plasticity.

“This experimental observation provides a rational basis for rectifying the inconsistency of study outcomes in Alzheimer’s disease clinical trials with IVIG. We now have the much needed information supporting the potential application of slow release of immunoglobulin´s delivered subcutaneously to delay the onset of Alzheimer’s disease, even at pre-symptomatic stages of the disease,” Dr. Pasinetti was quoted as saying.

SOURCE: Federation of American Societies for Experimental Biology, April 2012




comments powered by Disqus